Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Circio Holding ASA (CRNA.OL)
Oslo, NO
Circio Holding ASA, a biotechnology firm based in Oslo, Norway, and founded in 2010, specializes in the development of advanced circular RNA and immunotherapy treatments. Among its key innovations is TG01, a cancer vaccine aimed at specific driver mutations, which is currently progressing through three clinical trials for indications including multiple myeloma, pancreatic cancer, and lung cancer. The company also pioneers the circVec circRNA vector platform, an adaptable genetic module designed to facilitate the creation of diverse functional circular RNAs within human cells. This circVec platform is further supported by a collaborative agreement with Certest Biotec, S.L., focusing on its formulation. Formerly known as Targovax ASA, the company officially rebranded to Circio Holding ASA in May 2023.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +4.53% | +2.04% | -4.36% | +247.49% | +749.06% | +662.71% | +1,308.45% | -38.73% | +19.52% | +18.72% | +18.72% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-02 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%-109.1% Q4'22: -503.2% (vs Q4'21)
-
FCF margin FCF growth · Biotechnology: +16.2%-542.9% Q4'22: -285.7% (vs Q4'21)
-
EBIT margin Biotechnology: +0.0%-4,902.4% Q4'22: -4,128.2% (vs Q4'21)
-
ROIC Biotechnology: -16.1%-16,247.0% Q4'22: -46,496.5% (vs Q4'21)
-
Share dilution Biotechnology: -3.4%+111.5% Q4'22: +117.6% (vs Q4'21)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.67× Q4'22: -0.77× (vs Q4'21)
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|
| Revenue |
6.71M
est.
|
5.50M
est.
|
4.51M
4.51M – 4.51M
-18.1% YoY
|
3.69M
3.69M – 3.69M
-18.1% YoY
|
| EBITDA |
-4.03M
est.
|
-3.30M
est.
|
-2.70M
-2.70M – -2.70M
+18.1% YoY
|
-2.22M
-2.22M – -2.22M
+18.1% YoY
|
| EBIT |
-4.03M
est.
|
-3.30M
est.
|
-2.70M
-2.70M – -2.70M
+18.1% YoY
|
-2.22M
-2.22M – -2.22M
+18.1% YoY
|
| Net Income |
-20.99M
est.
|
-81.03M
est.
|
—
— – —
+100.0% YoY
|
—
— – —
|
| SGA |
591.48M
est.
|
484.60M
est.
|
397.03M
397.03M – 397.03M
-18.1% YoY
|
325.29M
325.29M – 325.29M
-18.1% YoY
|
| EPS |
-0.11
est.
|
-0.43
est.
|
—
— – —
+100.0% YoY
|
—
— – —
|
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Dimensional - International Small Cap ETF DFIS | 0.00% | 73.8K | 0.39% |
| 2 | Dimensional - International Core Equity 2 ETF DFIC | 0.00% | 21.0K | 0.22% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Erik Digman Wiklund | Chief Executive Officer | 3M | — |
| Lubor Gaal | Chief Financial Officer | 3M | — |
| Ola Melin | Chief Operating Officer | 3M | male |
| Thomas Birkballe Hansen | Chief Technology Officer | 2M | — |
| Victor Levitsky | Chief Scientific Officer | 2M | — |
| Jon Amund Eriksen | Special Advisor | 2M | male |
| Peter Skorpil | Vice President of Business Development | 1M | — |
| Gustav Gaudernack | Chief Scientific Adviser | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for CRNA.OL
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
